Immortalized Mesenchymal Stem Cells: A Safe Cell Source for Cellular or Cell Membrane-Based Treatment of Glioma

Figure 1

Immunophenotype, directed differentiation and functional properties of MSC and im-MSC. (a) Flow cytometry showing surface markers of mesenchymal stem cells from hADSC and hUCMSC. Immortalization of mesenchymal stem cells did not change the immunophenotype of mesenchymal stem cells. (b) As defined by ISCT, hADSC, hUCMSC, and immortalized mesenchymal stem cells, all have the ability to differentiate into osteoblasts (magnification, ×100), chondroblasts (magnification, ×200), and adipocytes (magnification, ×400). Scale bar, 400 μm. (c) Representative capillary tubule structures were shown for HUVECs treated with culture medium collected from the indicated MSC and im-MSC. magnification, ×200, scale bar, 100 μm. (d) Proliferation of PBMC co-cultured with MSC from different sources treated with mitomycin C. hADSC: human adipose-derived mesenchymal stem cells; hUCMSC: human umbilical cord mesenchymal stem cells; ISCT: International Society for Cell & Gene Therapy. , , , . ns: not significant.

(a)

(b)

(c)

(d)